Editas | GenomeWeb

Editas

The company intends to use part of the proceeds of the offering to advance programs including one in Leber congenital amaurosis 10.

The firm plans to sell 4 million shares of common stock to support preclinical studies and clinical trials of CRISPR-based human therapies, among other uses.

Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.

The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.

The licenses cover IP related to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

Editas has paid $1 million to test-drive Adverum's viral vectors in clinical gene editing and $1 million for an option on an exclusive license.

The Massachusetts-based clinical gene editing firm has obtained exclusive rights to use the engineered Cas9 variants developed by one of its co-founders.

The deal sets up a multi-year collaboration on hematopoietic stem cell and T-cell editing with the San Raffaele Telethon Institute for Gene Therapy.

CFFT will support drug discovery and development for cystic fibrosis while Editas will look into both common and uncommon mutations.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.